CERT on Nasdaq
Certara, Inc.
In its 2026 annual report the company says: “We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development in the global biopharmaceutical and biotech industry. In addition, MIDD strategies are increasingly utilized to help predict commercial success, a critical part of the drug research and development process as new products must be both approved by regulators and adopted by the market.”5 It is headquartered in Princeton, United States.2 Its shares trade on Nasdaq under the symbol CERT.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with AvePoint, Avid Technology or Grid Dynamics Holdings, or pick any stock.
- TickerCERT on Nasdaq2
- IndustryServices-Prepackaged Software2
- HeadquartersPrinceton, United States2
- Incorporated inDE3
- Business address4 Radnor Corporate Center, Suite 350, Radnor, Pa 190873
- Filer categoryLarge accelerated filer3
- Legal formCorporation2
- Kind of organizationLimited partnership2
- LEI549300EZJTHTM78UD6952
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 43112962
See how the biggest companies compare on our leaderboards
We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development (“MIDD”) in the global biopharmaceutical and biotech industry. MIDD is an approach that utilizes biological and statistical models derived from preclinical, clinical, and evidence data to inform decision-making in drug research and development, and commercialization. Biosimulation is a critical component of MIDD that uses computer-aided mathematical simulation of biological processes and systems to understand the action of a drug in a human body or a population of humans.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
5.0%Operating margin6
-0.4%Net margin6
8.7%Revenue growth, 20256
-0.2%Return on equity6
0.27×Debt to equity6
$94.6MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
Americas brought in 70% of the revenue Certara, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Americas | $265.1M | $281.5M | $291.6M |
| EMEA | $63.6M | $76.6M | $92.6M |
| Asia Pacific | $25.7M | $27.1M | $34.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development10¢$41.0M
- Other costs88¢$368.6M
- Income tax2¢$9.2M
Out of $418.8M in revenue.6 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending2¢$1.8M
- Share buybacks44¢$42.6M
- Kept or used elsewhere54¢$52.0M
Out of $96.3M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $418.8M | $385.1M | $354.3M |
| Cost of revenues | $161.1M | $154.5M | $141.0M |
| Sales and marketing | $53.7M | $47.4M | $32.0M |
| Research and development | $41.0M | $37.1M | $34.2M |
| General and administrative | $85.4M | $94.2M | $95.4M |
| Depreciation and amortization | $56.6M | $53.6M | $45.5M |
| Goodwill impairment expense | $0 | $0 | $47.0M |
| Total operating expenses | $236.7M | $232.4M | $254.1M |
| Income (loss) from operations | $21.0M | -$1.7M | -$40.8M |
| Interest expense | -$19.7M | -$21.5M | -$22.9M |
| Net other income | $6.3M | $6.1M | $8.5M |
| Total other expenses | -$13.4M | -$15.5M | -$14.4M |
| Income (loss) before income taxes | $7.6M | -$17.2M | -$55.1M |
| Provision (benefit) for income taxes | $9.2M | -$5.1M | $214.0K |
| Net loss | -$1.6M | -$12.1M | -$55.4M |
| Foreign currency translation adjustment, net of tax of $6, $(956), $(717) | $18.9M | -$3.2M | $2.7M |
| Change in fair value of interest rate swap, net of tax of $253, $$(827), $1,393 | -$3.4M | -$2.6M | -$2.1M |
| Total other comprehensive income (loss) | $15.5M | -$5.8M | $637.0K |
| Comprehensive income (loss) | $13.9M | -$17.9M | -$54.7M |
| Basic (in dollars per share) | -$0.01 | -$0.08 | -$0.35 |
| Diluted (in dollars per share) | -$0.01 | -$0.08 | -$0.35 |
| Basic (in shares) | 160.4M shares | 160.4M shares | 158.9M shares |
| Diluted (in shares) | 160.4M shares | 160.4M shares | 158.9M shares |
| Foreign currency translation adjustment, tax expense (benefit) | $6.0K | -$956.0K | -$717.0K |
| Change in fair value from interest rate swap, tax expense (benefit) | $253.0K | -$827.0K | $1.4M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $189.4M | $179.2M | ||
| Accounts receivable, net of allowances for credit losses of $2,235 and $2,164, respectively | $103.5M | $102.2M | ||
| Prepaid expenses and other current assets | $22.2M | $29.5M | ||
| Total current assets | $315.1M | $310.9M | ||
| Property and equipment, net | $1.9M | $2.2M | ||
| Operating lease right-of-use assets | $11.9M | $13.8M | ||
| Goodwill | $773.3M | $757.0M | $716.3M | |
| Intangible assets, net of accumulated amortization of $415,804 and $338,809, respectively | $447.5M | $485.2M | ||
| Deferred income taxes | $5.2M | $4.0M | ||
| Other long-term assets | $1.6M | $2.0M | ||
| Total assets | $1.6B | $1.6B | ||
| Accounts payable | $3.4M | $3.5M | ||
| Accrued expenses | $67.1M | $56.5M | ||
| Current portion of deferred revenue | $75.4M | $77.8M | ||
| Current portion of long-term debt | $3.0M | $3.0M | ||
| Other current liabilities | $4.5M | $5.3M | ||
| Total current liabilities | $153.4M | $146.1M | ||
| Deferred revenue, net of current portion | $2.4M | $1.0M | ||
| Deferred income taxes | $34.4M | $40.4M | ||
| Operating lease liabilities, net of current portion | $8.4M | $11.2M | ||
| Long-term debt, net of current portion and debt discount | $290.1M | $292.4M | ||
| Other long-term liabilities | $5.1M | $25.3M | ||
| Total liabilities | $493.8M | $516.4M | ||
| Preferred shares, $0.01 par value, 50,000,000 and no shares authorized, issued, and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common shares, $0.01 par value, 600,000,000 shares authorized, 164,005,450 and 161,958,810 shares issued as of December 31, 2025 and 2024, respectively; 159,139,562 and 161,009,112 shares outstanding as of December 31, 2025 and 2024, respectively | $1.6M | $1.6M | ||
| Additional paid-in capital | $1.3B | $1.2B | ||
| Accumulated deficit | -$129.9M | -$128.3M | ||
| Accumulated other comprehensive income(loss) | $2.0M | -$13.4M | ||
| Treasury stock at cost, 4,865,888 and 949,698 shares at December 31, 2025 and 2024, respectively | -$66.7M | -$18.2M | ||
| Total stockholders' equity | $1.1B | $1.1B | $1.0B | $1.1B |
| Total liabilities and stockholders' equity | $1.6B | $1.6B | ||
| Allowance for credit losses | $2.2M | $2.2M | ||
| Accumulated amortization | $415.8M | $338.8M | ||
| Preferred share, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred share, authorized (in shares) | 50.0M shares | 0 shares | ||
| Preferred share, issued (in shares) | 50.0M shares | 0 shares | ||
| Preferred share, outstanding (in shares) | 50.0M shares | 0 shares | ||
| Common share, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common share, authorized (in shares) | 600.0M shares | 600.0M shares | ||
| Common share, issued (in shares) | 164.0M shares | 162.0M shares | ||
| Common share, outstanding (in shares) | 159.1M shares | 161.0M shares | ||
| Treasury stock (in shares) | 4.9M shares | 949.7K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $189.4M | $179.2M | ||
| Accounts receivable, net of allowances for credit losses of $2,235 and $2,164, respectively | $103.5M | $102.2M | ||
| Prepaid expenses and other current assets | $22.2M | $29.5M | ||
| Total current assets | $315.1M | $310.9M | ||
| Property and equipment, net | $1.9M | $2.2M | ||
| Operating lease right-of-use assets | $11.9M | $13.8M | ||
| Goodwill | $773.3M | $757.0M | $716.3M | |
| Intangible assets, net of accumulated amortization of $415,804 and $338,809, respectively | $447.5M | $485.2M | ||
| Deferred income taxes | $5.2M | $4.0M | ||
| Other long-term assets | $1.6M | $2.0M | ||
| Total assets | $1.6B | $1.6B | ||
| Accounts payable | $3.4M | $3.5M | ||
| Accrued expenses | $67.1M | $56.5M | ||
| Current portion of deferred revenue | $75.4M | $77.8M | ||
| Current portion of long-term debt | $3.0M | $3.0M | ||
| Other current liabilities | $4.5M | $5.3M | ||
| Total current liabilities | $153.4M | $146.1M | ||
| Deferred revenue, net of current portion | $2.4M | $1.0M | ||
| Deferred income taxes | $34.4M | $40.4M | ||
| Operating lease liabilities, net of current portion | $8.4M | $11.2M | ||
| Long-term debt, net of current portion and debt discount | $290.1M | $292.4M | ||
| Other long-term liabilities | $5.1M | $25.3M | ||
| Total liabilities | $493.8M | $516.4M | ||
| Preferred shares, $0.01 par value, 50,000,000 and no shares authorized, issued, and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common shares, $0.01 par value, 600,000,000 shares authorized, 164,005,450 and 161,958,810 shares issued as of December 31, 2025 and 2024, respectively; 159,139,562 and 161,009,112 shares outstanding as of December 31, 2025 and 2024, respectively | $1.6M | $1.6M | ||
| Additional paid-in capital | $1.3B | $1.2B | ||
| Accumulated deficit | -$129.9M | -$128.3M | ||
| Accumulated other comprehensive income(loss) | $2.0M | -$13.4M | ||
| Treasury stock at cost, 4,865,888 and 949,698 shares at December 31, 2025 and 2024, respectively | -$66.7M | -$18.2M | ||
| Total stockholders' equity | $1.1B | $1.1B | $1.0B | $1.1B |
| Total liabilities and stockholders' equity | $1.6B | $1.6B | ||
| Allowance for credit losses | $2.2M | $2.2M | ||
| Accumulated amortization | $415.8M | $338.8M | ||
| Preferred share, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred share, authorized (in shares) | 50.0M shares | 0 shares | ||
| Preferred share, issued (in shares) | 50.0M shares | 0 shares | ||
| Preferred share, outstanding (in shares) | 50.0M shares | 0 shares | ||
| Common share, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common share, authorized (in shares) | 600.0M shares | 600.0M shares | ||
| Common share, issued (in shares) | 164.0M shares | 162.0M shares | ||
| Common share, outstanding (in shares) | 159.1M shares | 161.0M shares | ||
| Treasury stock (in shares) | 4.9M shares | 949.7K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$1.6M | -$12.1M | -$55.4M |
| Depreciation and amortization | $75.2M | $68.0M | $56.1M |
| Amortization of debt issuance costs | $568.0K | $1.0M | $1.5M |
| Provision for credit losses | $1.1M | $1.5M | $684.0K |
| Equity-based compensation expense | $33.1M | $34.8M | $28.3M |
| Change in fair value of contingent considerations | -$3.6M | $8.1M | $24.1M |
| Goodwill impairment | $0 | $0 | $47.0M |
| Total deferred | -$8.3M | -$12.7M | -$16.5M |
| Accounts receivable | $428.0K | -$16.2M | $152.0K |
| Prepaid and other assets | -$902.0K | -$2.9M | $711.0K |
| Accounts payable and accrued expenses, and other liabilities | $4.4M | -$4.8M | -$5.6M |
| Deferred revenue | -$3.0M | $13.8M | $28.0K |
| Other operating activities, net | -$1.0M | ||
| Other operating activities, net | $1.8M | $1.7M | |
| Net cash provided by operating activities | $96.3M | $80.5M | $82.8M |
| Capital expenditures | -$1.8M | -$1.6M | -$1.8M |
| Capitalized software development costs | -$24.8M | -$19.4M | -$13.5M |
| Investment in intangible assets | $0 | $0 | -$54.0K |
| Business acquisitions, net of cash acquired | $0 | -$91.3M | -$64.2M |
| Net cash used in investing activities | -$26.6M | -$112.4M | -$79.5M |
| Common stock repurchase program | -$42.6M | $0 | $0 |
| Proceeds from borrowings on term loan debt | $0 | $6.3M | $0 |
| Payment of debt issuance costs | $0 | -$1.2M | $0 |
| Payments on long-term debt obligations | -$3.0M | -$2.3M | -$3.0M |
| Payments for business acquisition related contingent consideration | -$13.2M | -$15.2M | $0 |
| Payment of taxes on shares and units withheld for employee taxes | -$5.2M | -$8.7M | -$6.4M |
| Net cash used in financing activities | -$64.0M | -$21.0M | -$9.4M |
| Effect of foreign exchange rate changes on cash and cash equivalents | $4.4M | -$2.9M | $1.5M |
| Net increase (decrease) in cash, cash equivalents | $10.2M | -$55.8M | -$4.7M |
| Cash paid for interest | $19.1M | $22.7M | $19.1M |
| Cash paid for taxes | $12.2M | $14.7M | $19.3M |
| Contingent liabilities established in connection with business acquisition | $0 | $0 | $11.3M |
| Stock issuance or establish liabilities related to business acquisition contingent consideration | $5.7M | $3.7M | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Certara, Inc. sits at the top of its group. 40 entities, 19 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Certara, Inc.
- DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G/A on Certara, Inc., latest Jul 14, 2026 (2 filings since Oct 9, 2025)
- BlackRock Filed SCHEDULE 13G/A on Certara, Inc., latest Jul 8, 2026 (2 filings since Jan 25, 2024)
- WASATCH ADVISORS LP Filed SCHEDULE 13G/A on Certara, Inc., latest Apr 6, 2026 (5 filings since Nov 13, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Certara, Inc., latest Mar 26, 2026 (4 filings since Feb 9, 2022)
- James E. Flynn Filed SCHEDULE 13G/A on Certara, Inc., latest Nov 25, 2025 (2 filings since Nov 13, 2025)
- ARSENAL CAPITAL PARTNERS III LP Filed SCHEDULE 13D/A on Certara, Inc., latest Apr 14, 2025 (2 filings since Dec 16, 2022)
- Mubadala Investment Co PJSC Filed SCHEDULE 13G/A on Certara, Inc., latest Feb 13, 2025
- BAILLIE GIFFORD & CO Filed SC 13G/A on Certara, Inc., latest Oct 4, 2024 (4 filings since Jan 12, 2022)
- EQT Avatar Parent L.P. Filed SC 13G/A on Certara, Inc., latest Feb 9, 2023 (2 filings since Feb 14, 2022)
- Certara, Inc. Princeton, New Jersey, United States
- Analytica LA-SER International, Inc. Subsidiary · Delaware, United States
- Applied BioMath, LLC Subsidiary · Delaware, United States
- BioMedCom Consultants, Inc. Subsidiary · Canada
- Certara (Shanghai) Pharmaceutical Consulting Co., Ltd. Subsidiary · China
- Certara Australia Pty Ltd Subsidiary · Australia
- Certara Brasil Software Ltda. Subsidiary · Brazil
- Certara Canada Corporation Subsidiary · Canada
- Certara France S.a.r.l. Subsidiary · France
- Certara G.K. Subsidiary · Japan
- Certara Germany GmbH Subsidiary · Germany
- Certara Holdco, Inc. Subsidiary · Delaware, United States
- Certara Holding, Inc. Subsidiary · Delaware, United States
- Certara Holdings, Inc. Subsidiary · Delaware, United States
- Certara Intermediate, Inc. Subsidiary · Delaware, United States
- Certara Italy S.r.l. Subsidiary · Italy
- Certara Netherlands B.V. Subsidiary · Netherlands
- Certara Philippines Inc. Subsidiary · Philippines
- Certara S.a.r.l. Subsidiary · Luxembourg
- Certara Software India Private Limited Subsidiary · India
- Certara Spain Sociedad Limitada Subsidiary · Spain
- Certara UK Holdings, Ltd. Subsidiary · United Kingdom
- Certara UK Limited Subsidiary · United Kingdom
- Certara USA, Inc. Subsidiary · Delaware, United States
- Certara, L.P. - Sucursal em Portugal (Branch) Subsidiary · Portugal
- Chemaxon GmbH Subsidiary · Switzerland
- and 14 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Certara, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $7.6M6 Dec 31, 2025 | $8.0M6 Dec 31, 2024 | −6.0% |
| Accumulated depreciation | $5.7M6 Dec 31, 2025 | $5.9M6 Dec 31, 2024 | −2.8% |
| Property and equipment, net | $1.9M6 Dec 31, 2025 | $2.2M6 Dec 31, 2024 | −14.5% |
| Operating-lease assets (leased space) | $11.9M6 Dec 31, 2025 | $13.8M6 Dec 31, 2024 | −13.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $189.4M6 Dec 31, 2025 | $179.2M6 Dec 31, 2024 | +5.7% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $773.3M6 Dec 31, 2025 | $757.0M6 Dec 31, 2024 | +2.1% |
| Finite-lived intangibles, gross | $863.3M6 Dec 31, 2025 | $824.0M6 Dec 31, 2024 | +4.8% |
| Accumulated amortization | $415.8M6 Dec 31, 2025 | $338.8M6 Dec 31, 2024 | +22.7% |
| Finite-lived intangibles, net | $447.5M6 Dec 31, 2025 | $485.2M6 Dec 31, 2024 | −7.8% |
Properties, in its own words
As of December 31, 2025, we had 28 offices in 16 countries, with our headquarters located in Radnor, Pennsylvania. We lease or sublease all of our offices. None of our facilities are used for anything other than general office use. We believe that our facilities are suitable and adequate for our operations and we anticipate that additional suitable space will be available when needed.
As of December 31, 2025, our material active operating locations, which we define as the facilities we lease with more than 10,000 square feet, were as follows:
The rest of Item 2
LOCATION · APPROXIMATESQUARE FOOTAGE · LEASE EXPIRATIONDATES
Sheffield, UK · 13,910 · 1/28/2028
Raleigh, North Carolina, USA · 11,250 · 1/31/2028
Radnor, Pennsylvania, USA · 19,370 · 12/31/2034
Budapest, Hungary · 24,810 · 12/31/2027
Item 2 of the 10-K filed Feb 26, 2026.5
Leadership
Who has led Certara, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerJon Matthew Resnick Jan 12, 2026 to now13
- Chief executive officerWilliam F. Feehery Dec 11, 2020 to Jan 12, 202614
- PresidentAdrian McKemey Mar 10, 2025 to Apr 3, 202515
- PresidentJohn E. Gallagher Apr 3, 2025 to now16
- PresidentDrayton Virkler Sep 9, 2022 to Apr 3, 202317
- PresidentCraig R. Rayner Jun 15, 2021 to Sep 7, 202118
- PresidentLeif E. Pedersen Dec 11, 2020 to Jun 15, 202119
- PresidentRobert Aspbury Dec 11, 2020 to Jun 15, 202120
- Chief financial officerJohn W. Reynders V. May 15, 2026 to Jul 17, 202621
- Chief financial officerFaiz Mohammed Jul 17, 2026 to now22
- Chief financial officerJohn E. Gallagher Apr 3, 2023 to May 15, 202623
- Chief financial officerMichael Andrew Schemick Dec 11, 2020 to Apr 3, 202324
Board members and other officers (22)
- Chief Human Resources OfficerRona Anhalt May 30, 2024 to now25
- OfficerCraig R. Rayner Dec 11, 2020 to Apr 9, 202126
- OfficerJieun W. Choe Dec 11, 2020 to Apr 5, 202227
- OfficerJudith Dickinson Dec 11, 2020 to Apr 9, 202128
- OfficerJustin Edge Dec 11, 2020 to Apr 5, 202229
- OfficerRichard M. Traynor Dec 11, 2020 to Dec 11, 202030
- Board memberJon Matthew Resnick Jan 12, 2026 to now13
- Board memberArjun Bedi Mar 2, 2026 to now31
- Board memberJohn W. Reynders V. Oct 18, 2024 to now32
- Board memberEran Broshy Jul 15, 2022 to now33
- Board memberRosemary A. Crane Jul 22, 2022 to now34
- Board memberDavid Spaight Dec 8, 2022 to Dec 8, 202235
- Board memberCarol Giltner Gallagher Jun 16, 2021 to Jun 16, 202136
- Board memberCynthia Collins Aug 2, 2021 to now37
- Board memberNancy Killefer Aug 2, 2021 to now38
- Board memberEthan Waxman Dec 11, 2020 to Dec 11, 202039
- Board memberJames E. Cashman Iii. Dec 11, 2020 to now40
- Board memberMason P. Slaine Dec 11, 2020 to Nov 16, 202241
- Board memberStephen M. McLean Dec 11, 2020 to Aug 23, 202242
- Board memberWilliam F. Feehery Dec 11, 2020 to now14
- General counselDaniel Corcoran May 30, 2024 to now43
- General counselRichard M. Traynor Dec 16, 2020 to Apr 3, 202444
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Analytica LA-SER International, Inc. Delaware4
- Applied BioMath, LLC Delaware4
- BioMedCom Consultants, Inc. Canada4
- Certara (Shanghai) Pharmaceutical Consulting Co., Ltd. China4
- Certara Australia Pty Ltd Australia4
- Certara Brasil Software Ltda. Brazil4
- Certara Canada Corporation Canada4
- Certara France S.a.r.l. France4
- Certara G.K. Japan4
- Certara Germany GmbH Germany4
- Certara Holdco, Inc. Delaware4
- Certara Holding, Inc. Delaware4
- Certara Holdings, Inc. Delaware4
- Certara Intermediate, Inc. Delaware4
- Certara Italy S.r.l. Italy4
- Certara Netherlands B.V. Netherlands4
- Certara Philippines Inc. Philippines4
- Certara S.a.r.l. Luxembourg4
- Certara Software India Private Limited India4
- Certara Spain Sociedad Limitada Spain4
- Certara UK Holdings, Ltd. England and Wales4
- Certara UK Limited England and Wales4
- Certara USA, Inc. Delaware4
- Certara, L.P. Delaware4
All 42 listed subsidiaries
- Certara, L.P. - Sucursal em Portugal (Branch) Portugal4
- Chemaxon GmbH Switzerland4
- Chemaxon Kft. Hungary4
- Chemaxon Limited England and Wales4
- Chemaxon Services, LLC Delaware4
- Chemaxon, LLC Delaware4
- Formedix Limited Scotland4
- INSTYTUT ARCANA sp. z o. o. Poland4
- Insight Medical Writing Limited England and Wales4
- Integrated Nonclinical Development Solutions, Inc. Michigan4
- La-Ser Europe Limited England and Wales4
- MBDD UK, LLC Delaware4
- MBDD US, L.L.C. Delaware4
- Pinnacle 21, Japan GK Japan4
- Pinnacle 21, LLC Delaware4
- Synchrogenix Information Strategies, LLC Delaware4
- Tripos Investments, L.L.C. Delaware4
- Vyasa Analytics, LLC Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 7, 20268-K Regulation FD disclosure47
- Aug 4, 20268-K Executive or director change48
- Aug 4, 20268-K Results of operations49
- Jun 17, 20268-K Executive or director change50
- May 15, 20268-K Shareholder vote51
- May 11, 20268-K Results of operations; Other events52
- Apr 22, 20268-K Entered a material agreement53
- Mar 31, 20268-K Executive or director change54
- Feb 26, 20268-K Results of operations55
- Jan 12, 2026New chief executive Jon Matthew Resnick becomes CEO13
- Dec 11, 20258-K Executive or director change56
- Nov 6, 20258-K Results of operations57
- Oct 16, 20258-K Entered a material agreement; New debt or obligation58
- Dec 11, 2020New chief executive William F. Feehery becomes CEO14
- Mar 2, 2007Founded Certara, Inc. is founded2
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.09 a share, on Nov 6, 2025.59
When it reported results
- Aug 4, 2026Reported quarterly or annual results49
- May 11, 2026Reported quarterly or annual results52
- Feb 26, 2026Reported quarterly or annual results55
- Nov 6, 2025Reported quarterly or annual results57
- Aug 6, 2025Reported quarterly or annual results60
- May 5, 2025Reported quarterly or annual results61
- Apr 14, 2025Reported quarterly or annual results62
- Feb 26, 2025Reported quarterly or annual results63
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
339 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 51 major events, 195 insider forms, 24 large holders, 3 private raises, 45 other. The latest 20:
- Sep 3, 2026144 EDGAR
- Sep 2, 20264 EDGAR
- Aug 7, 20268-K EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Aug 4, 20268-K EDGAR
- Jul 17, 20263 EDGAR
- Jul 14, 2026SCHEDULE 13G/A EDGAR
- Jul 8, 2026SCHEDULE 13G/A EDGAR
- Jun 17, 20268-K EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
- May 15, 20264 EDGAR
- May 15, 20264 EDGAR
- May 15, 20264 EDGAR
- May 15, 20264 EDGAR
- May 15, 20264 EDGAR
- May 15, 20264 EDGAR
- May 15, 20264 EDGAR
- May 15, 20264 EDGAR
The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
74 open-market trades by officers, directors and large owners since October 2021: 5 buys and 69 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2025 | Feehery William FCHIEF EXECUTIVE OFFICER | Buy | 24,096 | $8.30 | $200.0K | Form 4 |
| Sep 9, 2025 | Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF | Sale | 51,224 | $10.92 | $559.4K | Form 4 |
| Oct 7, 2024 | SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONS | Sale | 5,409 | $11.03 | $59.7K | Form 4 |
| Sep 9, 2024 | Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF | Sale | 51,224 | $11.29 | $578.3K | Form 4 |
| Apr 2, 2024 | SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONS | Sale | 14,427 | $16.85 | $243.2K | Form 4 |
| Apr 1, 2024 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 3,000 | $18.00 | $54.0K | Form 4 |
| Mar 4, 2024 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 3,000 | $18.28 | $54.8K | Form 4 |
| Feb 20, 2024 | SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONS | Sale | 5,000 | $18.00 | $90.0K | Form 4 |
| Feb 12, 2024 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 6,000 | $18.00 | $108.0K | Form 4 |
| Dec 26, 2023 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 6,000 | $18.00 | $108.0K | Form 4 |
| Sep 11, 2023 | Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF | Sale | 51,224 | $14.60 | $747.9K | Form 4 |
| Aug 22, 2023 | BROSHY ERANDirector | Buy | 4,807 | $15.80 | $76.0K | Form 4 |
| Aug 21, 2023 | BROSHY ERANDirector | Buy | 193 | $16.10 | $3.1K | Form 4 |
| Jun 5, 2023 | SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONS | Sale | 19,104 | $21.55 | $411.7K | Form 4 |
| May 11, 2023 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 5,000 | $20.82 | $104.1K | Form 4 |
| Apr 14, 2023 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 5,000 | $23.66 | $118.3K | Form 4 |
| Mar 6, 2023 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 10,000 | $21.45 | $214.5K | Form 4 |
| Feb 2, 2023 | Traynor Richard M.SVP AND GENERAL COUNSEL | Sale | 15,000 | $20.00 | $300.0K | Form 4 |
| Dec 8, 2022 | EQT Fund Management S.a r.l.10% owner | Sale | 29,954,521 | $15.00 | $449.3M | Form 4 |
| Nov 22, 2022 | Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF | Sale | 51,223 | $15.55 | $796.5K | Form 4 |
All 74 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- DIMENSIONAL FUND ADVISORS LPSCHEDULE 13G/A, 2 filings Oct 9, 2025 to Jul 14, 202664
- BlackRockSCHEDULE 13G/A, 2 filings Jan 25, 2024 to Jul 8, 202665
- WASATCH ADVISORS LPSCHEDULE 13G/A, 5 filings Nov 13, 2024 to Apr 6, 202666
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 9, 2022 to Mar 26, 202667
- James E. FlynnSCHEDULE 13G/A, 2 filings Nov 13, 2025 to Nov 25, 202568
- ARSENAL CAPITAL PARTNERS III LPSCHEDULE 13D/A, 2 filings Dec 16, 2022 to Apr 14, 202569
- Mubadala Investment Co PJSCSCHEDULE 13G/A, 1 filing Feb 13, 202570
- BAILLIE GIFFORD & COSC 13G/A, 4 filings Jan 12, 2022 to Oct 4, 202471
- EQT Avatar Parent L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 9, 202372
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | William F. FeeheryFormer Chief Executive Officer | $795.7K | $6.5M73 | |
| 2025 | John E. Gallagher IIISenior Vice President and CFO | $606.3K | $2.7M73 | |
| 2025 | Robert A. AspburyPresident, Certara Predictive Technologies | $457.7K | $2.0M73 | |
| 2025 | Leif E. PedersenPresident, Chief Commercial Officer | $458.4K | $1.9M73 | |
| 2025 | Adrian K. McKemeyPresident, Certara Drug Development Solutions | $366.7K | $1.9M73 | |
| 2024 | William F. FeeheryFormer Chief Executive Officer | $795.7K | $7.2M73 | |
| 2024 | John E. Gallagher IIISenior Vice President and CFO | $592.2K | $2.9M73 | |
| 2024 | Leif E. PedersenPresident, Chief Commercial Officer | $444.3K | $2.1M73 | |
| 2024 | Robert A. AspburyPresident, Certara Predictive Technologies | $378.2K | $2.0M73 | |
| 2023 | William F. FeeheryFormer Chief Executive Officer | $795.7K | $7.8M73 | |
| 2023 | John E. Gallagher IIISenior Vice President and CFO | $431.2K | $4.2M73 | |
| 2023 | Leif E. PedersenPresident, Chief Commercial Officer | $427.2K | $2.1M73 | |
| 2023 | Robert A. AspburyPresident, Certara Predictive Technologies | $337.6K | $2.1M73 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $14.3M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2026 | $8.6M | $8.6M |
| 2025 | $5.7M | $5.7M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
- Apr 15, 2026Raised $8.6 million in a private offering of equity46 Form D: 6 investors so far Form D
- Mar 24, 2025Raised $5.7 million in a private offering of equity74 Form D: 6 investors so far Form D
- Mar 27, 2024Filed a private offering of equity45 Form D: named in the filing: Cynthia Collins, Patrick Smith, Rosemary Crane, Nancy Killefer, Nicolette Sherman, Eran Broshy Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 18,818,180 | $123.3M | 0.0% | +4,510,302 |
| Deerfield Management Company, L.P. | 7,512,928 | $49.2M | 0.6% | −295,677 |
| Haveli Investment Management LLC | 7,400,000 | $48.5M | 26.9% | New |
| Jefferies Financial Group Inc. | 7,091,051 | $46.4M | 0.4% | +232,842 |
| Vanguard Portfolio Management LLC | 7,056,106 | $46.2M | 0.0% | +1,086,910 |
| Dimensional Fund Advisors LP | 6,022,686 | $39.4M | 0.0% | −2,539,822 |
| Vanguard Capital Management LLC | 5,283,180 | $34.6M | 0.0% | −77,249 |
| State Street Corp | 4,821,805 | $31.6M | 0.0% | +881,310 |
| Wasatch Advisors LP | 4,298,825 | $28.2M | 0.2% | −973,341 |
| Geode Capital Management, LLC | 3,141,689 | $20.6M | 0.0% | +1,027,133 |
| Fort Washington Investment Advisors Inc /oh/ | 2,864,204 | $18.8M | 0.1% | +188,661 |
| Royce & Associates LP | 2,756,026 | $18.1M | 0.1% | +1,540,975 |
| UBS Group AG | 2,666,456 | $17.5M | 0.0% | −754,176 |
| Millennium Management LLC | 2,555,126 | $16.7M | 0.0% | +1,299,182 |
| Morgan Stanley | 2,551,111 | $16.7M | 0.0% | −689,106 |
| First Trust Advisors LP | 2,424,222 | $15.9M | 0.0% | +1,508,738 |
| Aqr Capital Management LLC | 2,160,167 | $13.8M | 0.0% | +1,589,441 |
| Ameriprise Financial Inc | 2,030,844 | $13.3M | 0.0% | −217,015 |
| Systematic Financial Management LP | 1,892,050 | $12.4M | 0.2% | New |
| Kopion Asset Management, LLC | 1,858,539 | $12.2M | 7.7% | +570,087 |
| Bank Of America Corp /de/ | 1,798,449 | $11.8M | 0.0% | −244,497 |
| Boston Partners | 1,683,885 | $11.0M | 0.0% | New |
| Dixon Mitchell Investment Counsel Inc. | 1,545,956 | $10.1M | 0.3% | +8,080 |
| Quantinno Capital Management LP | 1,463,251 | $9.6M | 0.0% | +474,261 |
| Goldman Sachs Group Inc | 1,384,426 | $9.1M | 0.0% | +499,216 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Certara, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCertara, Inc.1
- CIK0001827090
- Employer ID (EIN)82-21809255
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)7372 Services-Prepackaged Software1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address4 Radnor Corporate Center, Suite 350, Radnor, PA 190871
- Phone(415) 237-82721
- Shares outstanding152,538,780 as of Aug 1, 202612
- Public float$1.4B as of Jun 30, 20255
- AuditorRSM US LLP, Blue Bell, Pennsylvania PCAOB ID 49; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceOct 8, 20201
- Filings464 in all: 4 (235), 8-K (61), 3 (35), 10-Q (17), 144 (16), SCHEDULE 13G/A (9), DEFA14A (8), SC 13G/A (8)1
All 35 form types
SC 13G (7), UPLOAD (7), 10-K (6), CORRESP (6), DEF 14A (6), 424B4 (4), ARS (4), D (4), DRS (4), EFFECT (4), S-1 (4), 4/A (2), S-1/A (2), SCHEDULE 13G (2), 10-K/A (1), 424B7 (1), 8-A12B (1), CERT (1), DRS/A (1), DRSLTR (1), FWP (1), PRE 14A (1), S-1MEF (1), S-3ASR (1), S-8 (1), SC 13D (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 4, 2026
Proxy statement (DEF 14A) Apr 3, 2026
Latest 8-K (8-K) Aug 7, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, par value $0.01 per share | CERT | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Certara, Inc. names in Item 1A of its 10-K filed Feb 26, 2026: 43 risks under these headings, as written.5
- Risks Related to Our Industry
- Deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development by regulatory authorities or academic institutions could damage our reputation or reduce the demand for our products and services.
- We compete in a competitive and highly fragmented market.
- Changes or delays in government regulation, executive action or administrative decision-making relating to the biopharmaceutical industry have decreased and could continue to decrease the need for some of the services we provide.
- Reduction in R&D spending by our customers for a variety of reasons, including due to lack of funding, as well as delays in the drug discovery and development process, have reduced and may continue to reduce demand for our products and services and negatively impact our results of operations and financial condition.
- Operational disruptions, funding constraints and policy changes at the FDA and other government agencies could adversely affect regulatory activity and our business
- Consolidation within the biopharmaceutical industry may reduce the pool of potential customers for our products and services or reduce the number of licenses for our software products.
- Risks Related to Our Business
- Our continued revenue growth depends on our ability to successfully increase our customer base, expand our relationships and the products and services we provide to our existing customers, and enter new markets and expand geographies.
- We depend on highly qualified personnel and may not be able to retain these employees or recruit additional qualified personnel, which could harm our business.
- If our independent contractors are characterized as employees, we could be subject to material adverse effects on our business and employment and withholding liabilities.
- Delays or defects in the release of new or enhanced software or other biosimulation tools may result in increased cost to us, delayed market acceptance of our products, diminished demand for our products, delayed or lost revenue, and liability.
The other 33 risks
- Issues relating to the implementation, use and development of AI and machine learning in our products and services may result in increased competition, reputational harm, regulatory action, or legal liability, and any failure to adapt to such technological developments or industry trends could adversely affect the performance of our business.
- If our existing customers do not renew their software licenses, do not buy additional solutions from us or renew at lower prices, our business and operating results will suffer.
- We have government customers and have received government grants, which subject us to risks including early termination, audits, investigations, sanctions, or penalties.
- We regularly evaluate potential acquisitions and other strategic transactions that we deem beneficial and strategic to our long-term growth and profitability, which could divert our management’s attention, result in additional dilution to our stockholders, and otherwise disrupt our operations and adversely affect our operating results.
- Our estimated addressable market is subject to inherent challenges and uncertainties. If we have overestimated the size of our addressable market or the various markets in which we operate, our future growth opportunities may be limited.
- Adverse global economic conditions could have a negative effect on our business, results of operations and financial condition and liquidity.
- We are subject to economic, political and other risks associated with the operation of a global business that could negatively affect our business, results of operations and financial condition.
- Our failure to comply with trade compliance and economic sanctions laws and regulations of the United States and other applicable international jurisdictions could materially adversely affect our reputation and results of operations.
- Current and future litigation against us, which may arise in the ordinary course of our business, could be costly and time consuming to defend.
- Our insurance coverage may not be sufficient to avoid material impact on our financial position resulting from claims or liabilities against us, and we may not be able to obtain insurance coverage on attractive terms, or at all, in the future.
- If we fail to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations, we could be liable for significant costs or penalties and our reputation could be harmed.
- We derive a significant percentage of our revenues from a key group of customers, and the loss of one or more of our major customers could materially and adversely affect our business, results of operations and/or financial condition.
- We may need additional funding. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, results of operations, and financial condition.
- Our bookings might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our bookings.
- We are subject to the FCPA and the U.K. Bribery Act and similar anti-corruption laws and regulations in other countries and jurisdictions. Violations of these laws and regulations could harm our reputation and business, or materially adversely affect our business, results of operations, financial condition and/or cash flows.
- Our business may be subject to risks arising from catastrophic events, including natural disasters, significant or extreme weather events, outbreaks of war or terrorism, epidemic diseases, pandemics, and public health crises.
- Evolving corporate governance and public disclosure regulations and expectations, including with respect to sustainability matters, could expose us to risks.
- Risks Related to Intellectual Property, Information Technology and Data Privacy
- We rely on third-party providers of cloud-based infrastructure to host our software solutions. Any disruption in the operations of these third-party providers, limitations on capacity or interference with our use could adversely affect our business, financial condition, reputation and results of operations.
- If our cybersecurity measures are breached or unauthorized or unlawful access to customer or other proprietary data occurs, our solutions may be perceived as not being secure, customers may reduce the use of or stop using our solutions and/or we may incur significant liabilities.
- We are subject to numerous privacy and cybersecurity laws and related contractual requirements, and our failure to comply with those obligations could cause us significant harm, including financial losses and reputational harm.
- If we are not able to reliably meet our data storage and management or other information technology requirements, or if we experience any technology failures in the delivery of our services over the internet or in the administration of our business, customer satisfaction and our reputation could be harmed and customer contracts may be terminated.
- Some of our software solutions utilize third-party open source software, and any failure to comply with the terms of one or more of these open source licenses could adversely affect our business, subject us to litigation and create potential liability.
- We may be unable to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights.
- Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
- If we fail to comply with certain healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
- Risks Related to Our Indebtedness
- Our indebtedness could materially adversely affect our financial condition and our ability to operate our business, react to changes in the economy or industry or pay our debts and meet our obligations under our debt and could divert our cash flow from operations to debt payments.
- Restrictive covenants governing our Credit Agreement may restrict our ability to pursue our business strategies, and failure to comply with any of these restrictions could result in acceleration of our debt.
- Risks Related to our Financial Statements and Results
- Impairment of goodwill or other intangible assets may adversely impact future results of operations.
- Our ability to use our net operating losses (“NOLs”) and R&D tax credit carryforwards to offset future taxable income may be subject to certain limitations.
- Risks Related to Ownership of Our Common Stock
- The market price of our common stock has been and may continue to be volatile, and may decline regardless of our operating performance, which could cause the value of your investment to decline.
- Future sales, or the perception of future sales, of our common stock by us or our existing stockholders in the public market could cause the market price for our common stock to decline.
- Arsenal holds a substantial amount of our outstanding common stock, and its interests may be different than the interests of other holders of our common stock.
- Our amended and restated certificate of incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America will be the sole and exclusive forums for certain stockholder litigation matters, which could limit our stockholder’s ability to obtain a favorable judicial forum for disputes with us or our current and former directors, officers, employees or stockholders.
Legal proceedings
To the extent applicable, the information required with respect to this item can be found under Note 11. “Commitments and Contingencies” in the notes to the consolidated financial statements and is incorporated by reference into this Item 3.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCertara, Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARCertara, Inc. filings on SEC EDGAR
- 4
- 5
- 6SEC EDGARCertara, Inc. 10-K for fiscal 2025
- 7SEC EDGARCertara, Inc. 10-K for fiscal 2019
- 8SEC EDGARCertara, Inc. 10-K for fiscal 2020
- 9SEC EDGARCertara, Inc. 10-K for fiscal 2021
- 10SEC EDGARCertara, Inc. 10-K for fiscal 2022
- 11SEC EDGARCertara, Inc. 10-Q for fiscal 2026
- 12SEC EDGARCertara, Inc. 10-Q for fiscal 2026
- 13
- 14
- 15SEC EDGARAdrian McKemey, President
- 16SEC EDGARJohn E. Gallagher, President
- 17SEC EDGARDrayton Virkler, President
- 18SEC EDGARCraig R. Rayner, President
- 19SEC EDGARLeif E. Pedersen, President
- 20SEC EDGARRobert Aspbury, President
- 21
- 22
- 23
- 24
- 25
- 26SEC EDGARCraig R. Rayner, Officer
- 27SEC EDGARJieun W. Choe, Officer
- 28SEC EDGARJudith Dickinson, Officer
- 29SEC EDGARJustin Edge, Officer
- 30SEC EDGARRichard M. Traynor, Officer
- 31SEC EDGARArjun Bedi, Board member
- 32SEC EDGARJohn W. Reynders V., Board member
- 33SEC EDGAREran Broshy, Board member
- 34SEC EDGARRosemary A. Crane, Board member
- 35SEC EDGARDavid Spaight, Board member
- 36
- 37SEC EDGARCynthia Collins, Board member
- 38SEC EDGARNancy Killefer, Board member
- 39SEC EDGAREthan Waxman, Board member
- 40SEC EDGARJames E. Cashman Iii., Board member
- 41SEC EDGARMason P. Slaine, Board member
- 42SEC EDGARStephen M. McLean, Board member
- 43SEC EDGARDaniel Corcoran, General counsel
- 44SEC EDGARRichard M. Traynor, General counsel
- 45
- 46
- 47SEC EDGARRegulation FD disclosure
- 48SEC EDGARExecutive or director change
- 49SEC EDGARResults of operations
- 50SEC EDGARExecutive or director change
- 51SEC EDGARShareholder vote
- 52SEC EDGARResults of operations; Other events
- 53SEC EDGAREntered a material agreement
- 54SEC EDGARExecutive or director change
- 55SEC EDGARResults of operations
- 56SEC EDGARExecutive or director change
- 57SEC EDGARResults of operations
- 58
- 59NasdaqNasdaq calendar
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74